NICA Stock Overview
A nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science applications worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Nanologica AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 5.08 |
| 52 Week High | SEK 12.70 |
| 52 Week Low | SEK 4.49 |
| Beta | 0.49 |
| 11 Month Change | -16.72% |
| 3 Month Change | -6.27% |
| 1 Year Change | -52.96% |
| 33 Year Change | -63.19% |
| 5 Year Change | -57.67% |
| Change since IPO | -76.80% |
Recent News & Updates
Recent updates
Nanologica (STO:NICA) Is Making Moderate Use Of Debt
Oct 10
Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?
Jun 12Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?
Oct 20Nanologica (STO:NICA) Is Making Moderate Use Of Debt
Jun 23Is Nanologica (NGM:NICA) A Risky Investment?
Jan 03Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?
Jun 14Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%
Feb 23Shareholder Returns
| NICA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -8.6% | -5.9% | -6.7% |
| 1Y | -53.0% | 13.3% | 9.9% |
Return vs Industry: NICA underperformed the Swedish Biotechs industry which returned 13.3% over the past year.
Return vs Market: NICA underperformed the Swedish Market which returned 9.9% over the past year.
Price Volatility
| NICA volatility | |
|---|---|
| NICA Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: NICA's share price has been volatile over the past 3 months.
Volatility Over Time: NICA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 16 | Andreas Bhagwani | www.nanologica.com |
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science applications worldwide. The company operates through two segments, Drug Development and Chromatography. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA HPLC analytical columns.
Nanologica AB (publ) Fundamentals Summary
| NICA fundamental statistics | |
|---|---|
| Market cap | SEK 224.43m |
| Earnings (TTM) | -SEK 76.29m |
| Revenue (TTM) | SEK 8.50m |
26.4x
P/S Ratio-2.9x
P/E RatioIs NICA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NICA income statement (TTM) | |
|---|---|
| Revenue | SEK 8.50m |
| Cost of Revenue | SEK 5.06m |
| Gross Profit | SEK 3.44m |
| Other Expenses | SEK 79.72m |
| Earnings | -SEK 76.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 40.44% |
| Net Profit Margin | -898.03% |
| Debt/Equity Ratio | 419.8% |
How did NICA perform over the long term?
See historical performance and comparison